BofA sees higher gold prices, likely to hit $5,000/oz in 2026
Investing.com - Leerink Partners has lowered its price target on Procept BioRobotics Corp (NASDAQ:PRCT) to $55.00 from $65.00 while maintaining an Outperform rating following the company’s third-quarter 2025 earnings report. The new target remains significantly above the current trading price of $35.02, with InvestingPro data showing the stock has fallen 56.5% year-to-date and is trading 66% below its 52-week high of $103.81.
The medical device company delivered a 3% revenue beat in the third quarter, with U.S. system sales of 57 units exceeding consensus expectations of 52 units, according to Leerink Partners’ analysis. InvestingPro data reveals Procept’s impressive revenue growth of 55.7% over the last twelve months, though the company remains unprofitable with a negative EBITDA of $85.9 million.
Procept BioRobotics also issued preliminary fiscal year 2026 revenue guidance of $410 million to $430 million, compared to consensus estimates of $427.5 million, potentially alleviating investor uncertainty regarding growth expectations under recently appointed CEO Larry Wood. This guidance aligns with the company’s strong five-year revenue CAGR of 105%, according to InvestingPro metrics.
Despite these positive developments, Leerink Partners noted several concerns that could face investor scrutiny, including third-quarter utilization falling 1% below consensus, implied fourth-quarter revenue tracking 3% below consensus, and management commentary about handpiece destocking and elongated capital purchases.
The research firm acknowledged that Procept BioRobotics might remain a "battleground stock" in the near term but continues to see a positive risk-reward profile due to the company’s Aquablation technology’s competitive position within the large, underpenetrated resective BPH (benign prostatic hyperplasia) market.
In other recent news, PROCEPT BioRobotics reported its third-quarter 2025 earnings, surpassing revenue expectations with $83.3 million, marking a 43% increase compared to the previous year. The company’s earnings per share (EPS) stood at -$0.38, slightly better than the anticipated -$0.41. These financial results indicate a stronger performance than analysts had projected. While the earnings release was followed by a modest stock movement, specific details on stock prices are not the focus here. The significant revenue growth highlights the company’s current business trajectory. Analysts from various firms have yet to provide upgrades or downgrades following this earnings announcement. These developments are part of the company’s recent activities and reflect its financial health. Investors are likely to keep a close eye on future earnings reports for further insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.